Delivery Order SPE2DB20D3505-SPE2DB25FU7M4
- Not listed
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,527.14 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with completion targeted for August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award executed under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied from the...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a $11,458.33 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on June 13, 2025, with an ultimate completion date of June 16, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $4,630.35 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed price delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,906.97 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract uses firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a $6,356.88 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,954.69 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This non-competitive, firm fixed-price delivery order was issued under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,724.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FU7M4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,797.68 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 4, 2025, with completion scheduled for June 5, 2025. This non-set-aside, firm fixed-price delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. This delivery order for Dupixent, a biologic medication used to treat conditions such as atopic dermatitis and eosinophilic asthma, represents a routine fulfillment under the DLA's pharmaceutical prime vendor program, which enables efficient procurement and distribution of medical supplies to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 6/4/25 |